ACET Stock Forecast & Price Target

Adicet Bio is viewed positively because prula-cel has shown a compelling balance of efficacy and safety in heavily pretreated lupus patients, with 50% complete renal response at 12 months, 54% DORIS remission, and all 12-month responses remaining ongoing through 12 to 21 months. The case is further strengthened by a best-in-class tolerability profile, with no CRS above Grade 2, no ICANS, no GvHD, and all patients discontinuing background immunosuppressants, while immune-reset biomarkers such as undetectable CD19+ B cells and naive-dominant reconstitution support durability. Near-term catalysts also improve the outlook, including pivotal LN study start-up, FDA discussions in 4Q26 on expanding into non-nephritis lupus, a regulatory update plus ~22-patient follow-up in 1Q27, and ADI-212 receiving IND clearance and Fast Track designation with initiation in 1Q27.

Adicet Bio is viewed negatively because its value depends on early-stage clinical programs that could be derailed by trial delays, safety signals, or broader regulatory setbacks, any of which would materially weaken confidence in prulacabtagene leucel and ADI-212. The company also faces meaningful execution risk in lupus and other autoimmune indications, where failure to show efficacy would leave the pipeline without a clear commercial path and expose it to rising competitive pressure. Financially, as a clinical-stage biotech that is not yet cash flow positive, it remains dependent on future capital raises in public or private markets, creating ongoing dilution and funding risk.